The Latest Cardiac and Vascular News
Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with […]
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern […]
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship […]
Phase 1 healthy volunteer study demonstrates that oral administration of IMB-101 is well tolerated and exhibits predictable pharmacokinetic characteristics Pre-clinical study showed that IMB-101 improves cardiac contractile function and fibrosis post-myocardial infarction, highlighting its therapeutic potential in the context of myocardial ischemia and heart failure BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical […]
AT-01 detected cardiac amyloid in AL and ATTR patients with known cardiac disease with 95% sensitivity AT-01 detected cardiac amyloid in patients with AL or ATTR amyloid with normal levels of serum NT-proBNP AT-01 has the potential to distinguish AL and ATTR amyloidosis based on organ distribution SOUTH SAN FRANCISCO, […]
Mavacamten, a potential first-in-class cardiac myosin inhibitor for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), showed improvement in health status compared to placebo at 30 weeks in EXPLORER-HCM trial Findings of new analysis published simultaneously in The Lancet PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced a new analysis of data […]
Minimally-invasive, implant-free technology for heart failure patients studied at 1 and 3 months AUSTIN, Texas–(BUSINESS WIRE)–Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved […]
Positive results from the landmark PzF SHIELD IDE clinical trial reinforce safe and effective use in a real-world clinical practice of the world’s first non-drug-eluting, nanocoated coronary stent. SAN ANTONIO, May 13, 2021 /PRNewswire/ — CeloNova BioSciences, Inc. (CeloNova), a global medical device company that offers a family of innovative products based upon its […]
TAMPA, Fla., May 12, 2021 /PRNewswire/ — Tampa General Hospital and USF Health’s Interventional Cardiology team has adopted new intravascular technology and successfully treated the first patient in the world. Tampa General has built a legacy as an early adopter of intravascular imaging for coronary intervention and continues to seek the newest and […]
Heart & Vascular Institute Expansion and Community Partnerships Lead to Decrease in Heart-Related Deaths EDGEWOOD, Ky., May 13, 2021 /PRNewswire/ — St. Elizabeth Healthcare is increasing access to quality cardiac care in the Northern Kentucky community with system-wide enhancements to the Heart & Vascular Institute (HVI), including the construction of a new, 67,000-square-foot facility in Edgewood and expansions to the […]
